<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vitamin K (phytonadione, phytomenadione): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vitamin K (phytonadione, phytomenadione): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vitamin K (phytonadione, phytomenadione): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9771" href="/d/html/9771.html" rel="external">see "Vitamin K (phytonadione, phytomenadione): Drug information"</a> and <a class="drug drug_patient" data-topicid="11567" href="/d/html/11567.html" rel="external">see "Vitamin K (phytonadione, phytomenadione): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709210"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions with IV and IM use:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fatal hypersensitivity reactions, including anaphylaxis, have occurred during and immediately after IV and IM injection of phytonadione. Reactions have occurred despite dilution to avoid rapid IV infusion and upon first dose. Avoid the IV and IM routes of administration unless the SUBQ route is not feasible and the serious risk is justified.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F209759"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Mephyton</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52914130"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AquaMEPHYTON;</li>
<li>Konakion;</li>
<li>Mephyton</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1061083"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Nutritional Supplement</span>;</li>
<li>
<span class="list-set-name">Vitamin, Fat Soluble</span></li></ul></div>
<div class="block don drugH1Div" id="F53462545"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Dosing presented in <b>mcg</b> and mg; verify dosing units.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommended oral intake:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates: Oral: 8 to 10 <b>mcg</b>/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22730042']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22730042'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates: Oral: 2 <b>mcg</b>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22730042','lexi-content-ref-IOM.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22730042','lexi-content-ref-IOM.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e69afa9e-557e-43f1-9b39-f55cc1e5831e">Parenteral nutrition, maintenance requirement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition, maintenance requirement:</b></p>
<p style="text-indent:-2em;margin-left:4em;">ASPEN recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22730042']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22730042'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm neonates: IV: 10 <b>mcg</b>/kg/day as an additive to parenteral nutrition solution.</p>
<p style="text-indent:-2em;margin-left:6em;">Term neonates: IV: 200 <b>mcg</b>/day as an additive to parenteral nutrition solution.</p>
<p style="text-indent:-2em;margin-left:4em;">ESPGHAN/ESPEN/ESPR/CSPEN recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30100105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30100105'])">Ref</a></span>): Preterm and term neonates: IV: 10 <b>mcg</b>/kg/day as an additive to parenteral nutrition solution.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fe6a8a28-847b-4a9f-8fd4-36edcf9f47da">Vitamin K deficiency bleeding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin K deficiency bleeding (formerly known as hemorrhagic disease of the newborn): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">IM: <b>Note:</b> Administer within 6 hours of birth (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35190810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35190810'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>AAP recommendations</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35190810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35190810'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">Preterm and term neonates:</p>
<p style="text-indent:-2em;margin-left:12em;">Birth weight ≤1,500 g: IM: 0.3 to 0.5 mg/kg once.</p>
<p style="text-indent:-2em;margin-left:12em;">Birth weight &gt;1,500 g: IM: 1 mg once.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Canadian Paediatric Society</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30315016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30315016'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">Preterm and term neonates:</p>
<p style="text-indent:-2em;margin-left:12em;">Birth weight ≤1,500 g: IM: 0.5 mg once.</p>
<p style="text-indent:-2em;margin-left:12em;">Birth weight &gt;1,500 g: IM: 1 mg once.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: <b>Note:</b> IM therapy is preferred. Oral therapy may be considered if parenteral vitamin K preparations are not available or it is not possible to administer IM (eg, parental refusal) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-30315016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-30315016'])">Ref</a></span>). Incomplete oral therapy may leave infant at risk for late-onset vitamin K deficient bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35190810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35190810'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Term infants with no comorbid conditions:</p>
<p style="text-indent:-2em;margin-left:10em;">3-dose series: Oral: 2 mg on day of life (DOL) 1, then 2 mg at 1 to 2 weeks of age, and 2 mg at 4 weeks of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>). <b>Note:</b> An alternate schedule of 2 mg on DOL 1 (with first feeding), 2 mg at 2 to 4 weeks of age, and 2 mg at 6 to 8 weeks of age has also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30315016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30315016'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Weekly dosing: Oral: 2 mg on DOL 1, then 1 mg once weekly for 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27050049']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27050049'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i> Preterm and term neonates: SUBQ, IM, IV: 1 mg/dose; correction may take 12 to 48 hours; other treatments may be necessary (eg, fresh frozen plasma, platelets). Higher doses may be necessary if mother was receiving anticoagulant therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Croteau.1','lexi-content-ref-Dror.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Croteau.1','lexi-content-ref-Dror.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F209784"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Dosing presented in <b>mcg</b> and mg; verify dosing units.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Route of administration varies with indication; careful evaluation of route of administration is important. The oral route is preferred in the treatment of <b>nonbleeding</b> patients with warfarin-associated coagulopathy; SubQ administration has fallen out of favor for this indication due to erratic and unpredictable absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12186515','lexi-content-ref-16505257','lexi-content-ref-10597763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12186515','lexi-content-ref-16505257','lexi-content-ref-10597763'])">Ref</a></span>). The IV route may be used in select <b>nonbleeding</b> patients and should be used in patients with <b>major bleeding</b> due to warfarin-associated coagulopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-12181071']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-12181071'])">Ref</a></span>). The IV and SubQ routes may be used in the treatment of vitamin K deficiency bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>). The IM route should be avoided due to the risk of hematoma formation except in the prevention/treatment of vitamin K deficiency bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12181071','lexi-content-ref-Eichenwald.1','lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12181071','lexi-content-ref-Eichenwald.1','lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e69afa9e-557e-43f1-9b39-f55cc1e5831e">Parenteral nutrition, maintenance requirement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition, maintenance requirement:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22730042','lexi-content-ref-30100105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22730042','lexi-content-ref-30100105'])">Ref</a></span>): <b>Note:</b> Patients receiving warfarin may not require TPN supplementation of phytonadione.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: IV: 10 <b>mcg</b>/kg/day as an additive to parenteral nutrition solution.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 200 <b>mcg</b>/day as an additive to parenteral nutrition solution.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e40fad22-ca9c-43e8-b5c0-46b4dcdc937a">Reversal of vitamin K antagonists</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of vitamin K antagonists (eg, warfarin):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-based dosing (preferred): <i>Chest</i> recommendations: IV: 0.03 mg/kg/dose is recommended for excessively prolonged INR (usually INR &gt;8; no evidence of bleeding) due to vitamin K-antagonist (eg, warfarin): if significant bleeding, consider use of fresh frozen plasma, prothrombin complex concentrates, or recombinant factor VIIa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-12181071']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-12181071'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing: <b>Note:</b> Smaller pediatric patients should receive doses on the low end of dosing range; excessive dosages may cause warfarin-resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12181071','lexi-content-ref-9822076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12181071','lexi-content-ref-9822076'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">No bleeding, rapid reversal needed, patient will require further oral anticoagulant therapy: SubQ, IV: 0.5 to 2 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">No bleeding, rapid reversal needed, patient will not require further oral anticoagulant therapy: SubQ, IV: 2 to 5 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">Significant bleeding, not life-threatening: SubQ, IV: 0.5 to 2 mg; <b>Note: </b>Use in combination with fresh frozen plasma.</p>
<p style="text-indent:-2em;margin-left:8em;">Significant bleeding, life-threatening: SubQ, IV: 5 mg; <b>Note: </b>Consider use with prothrombin complex concentrate containing factors II, VII, IX, X.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d22c7c1d-a797-4911-8d2e-00415566b009">Vitamin K deficiency, prevention, and supplementation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin K deficiency, prevention, and supplementation (disease-specific):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Biliary atresia</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22891232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22891232'])">Ref</a></span>): <b>Note:</b> Dose and route are determined by INR value:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants 1 to 6 months:</p>
<p style="text-indent:-2em;margin-left:8em;">INR &gt;1.2 to 1.5: 2.5 mg once daily orally.</p>
<p style="text-indent:-2em;margin-left:8em;">INR &gt;1.5 to 1.8: Initial: 2 to 5 mg IM once followed by 2.5 mg once daily orally.</p>
<p style="text-indent:-2em;margin-left:8em;">INR &gt;1.8: Initial: 2 to 5 mg IM once followed by 5 mg once daily orally.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cholestasis:</i> Infants, Children, and Adolescents: Oral: 2.4 to 15 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20702838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20702838'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystic fibrosis:</i> Infants, Children, and Adolescents: Oral: 0.3 to 0.5 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12352509','lexi-content-ref-20702838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12352509','lexi-content-ref-20702838'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Liver disease:</i> Infants, Children, and Adolescents: Oral: 2.5 to 5 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19931069','lexi-content-ref-20702838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19931069','lexi-content-ref-20702838'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51153603"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51153604"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; dosing adjustment unlikely necessary.</p></div>
<div class="block doa drugH1Div" id="F209763"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9771" href="/d/html/9771.html" rel="external">see "Vitamin K (phytonadione, phytomenadione): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Due to risk of a severe infusion reaction, including anaphylaxis, the maximum rate of IV administration is 1 mg/minute.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e27cd063-b38e-4964-abb7-a386ea2618a8">Reversal of anticoagulation due to warfarin or other coumarin or indandione derivatives</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of anticoagulation due to warfarin or other coumarin or indandione derivatives:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Dose and route depend on the severity of bleeding and/or INR.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Urgent reversal:</b> IV administration is recommended. For life-threatening bleeding, vitamin K should be administered in combination with clotting factors (eg, 4-factor prothrombin complex concentrate [PCC], or fresh frozen plasma if 4-factor PCC is not available) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31171018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31171018'])">Ref</a></span>). Following IV administration, reversal begins in ~2 hours with expected full reversal within 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-31446606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-31446606'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Nonurgent reversal:</b> Oral administration is recommended to reduce INR in ~24 to 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315269','lexi-content-ref-22315259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315269','lexi-content-ref-22315259'])">Ref</a></span>). <b>Avoid other routes:</b> SUBQ administration is not recommended due to unpredictable absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12186515','lexi-content-ref-16505257','lexi-content-ref-10597763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12186515','lexi-content-ref-16505257','lexi-content-ref-10597763'])">Ref</a></span>). Avoid IM administration due to risk of hematoma formation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Usual dosage range:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 2.5 to 10 mg, depending on the INR. Administer as a single dose. Measure INR after 12 to 48 hours and administer another dose as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: 2.5 to 10 mg, depending on the INR and severity of bleeding. Administer as a single dose over 10 to 20 minutes (maximum infusion rate: 1 mg/minute). Measure INR after 6 to 12 hours and administer another dose as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> High doses of vitamin K (eg, &gt;10 to 15 mg) may cause warfarin resistance for ≥1 week; if anticoagulation is needed, an alternative agent may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18574265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18574265'])">Ref</a></span>).</p>
<table border="1" data-table-id="example" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Reversal of Anticoagulation From Warfarin</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Indication</p></th>
<th align="center">
<p style="text-indent:0em;">Management considerations</p></th>
<th align="center">
<p style="text-indent:0em;">Vitamin K administration</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>1 mg oral dose may be administered using 0.5 mL of 2 mg/mL parenteral preparation by mouth.</p>
<p style="text-indent:0em;">
<sup>b </sup>Patriquin 2011.</p>
<p style="text-indent:0em;">
<sup>c </sup>ACCP [Hirsh 2008].</p>
<p style="text-indent:0em;">
<sup>d </sup>ACCP [Holbrook 2012].</p>
<p style="text-indent:0em;">
<sup>e </sup>ASH [Witt 2018].</p>
<p style="text-indent:0em;">
<sup>f </sup>AHA/ACC [Nishimura 2014]; ACC/AHA [Otto 2021].</p>
<p style="text-indent:0em;">
<sup>g </sup>Farrow 2020.</p>
<p style="text-indent:0em;">
<sup>h </sup>PCC=prothrombin complex concentrate.</p>
<p style="text-indent:0em;">
<sup>i </sup>ACCP [Ageno 2012].</p>
<p style="text-indent:0em;">
<sup> j </sup>NCS/SCCM [Frontera 2016].</p>
<p style="text-indent:0em;">
<sup>k </sup>ACCP [Douketis 2022].</p>
<p style="text-indent:0em;">
<sup>l</sup> Douketis 2021.</p>
<p style="text-indent:0em;">
<sup>m</sup> Hull 2022.</p>
<p style="text-indent:0em;">
<sup>n</sup> ACC [Doherty 2017].</p>
<p style="text-indent:0em;">
<sup>o</sup> Nkomo 2023.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<b>
<i>Supratherapeutic INR and no evidence of bleeding</i></b></p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR above therapeutic range but &lt;4.5</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Consider holding the next dose of warfarin and/or reduce maintenance dose; increase INR monitoring.</p>
<p style="text-indent:0em;">Elevated INR may be due to transient factors, so warfarin dose reduction is not always necessary.</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Routine administration of vitamin K is not recommended.<sup>b</sup></p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 4.5 to 10</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Discontinue warfarin, monitor INR frequently, and resume an appropriately reduced warfarin dose when INR is in desired range.</p>
<p style="text-indent:0em;">May consider administering oral vitamin K if additional risk factors for bleeding exist.</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Routine administration of vitamin K is not recommended.</p>
<p style="text-indent:0em;">If administered, one dose of <b>oral </b>vitamin K 1 to 2.5 mg is recommended.<sup>a,c,d,e,f</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">INR &gt;10</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue warfarin, monitor INR frequently, and resume an appropriately reduced warfarin dose when INR is in desired range.</p>
<p style="text-indent:0em;">Consider administering oral vitamin K depending on bleeding and thrombotic risks.</p></td>
<td align="center">
<p style="text-indent:0em;">If administered, one dose of <b>oral</b> vitamin K 2.5 to 5 mg is usually recommended; recheck INR after 12 to 24 hours; may administer a second dose if necessary.<sup>c,d</sup></p>
<p style="text-indent:0em;">For patients with a mechanical prosthetic heart valve, a lower <b>oral</b> vitamin K dose of 1 to 2.5 mg may be administered to avoid overcorrection of INR.<sup>a,f</sup></p>
<p style="text-indent:0em;">Some data suggest that vitamin K is not routinely needed in the absence of bleeding.<sup>g</sup></p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>
<b>Bleeding</b></i></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Minor bleeding</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue warfarin, monitor INR frequently, and resume warfarin at an appropriately adjusted dose when it is safe to do so.</p>
<p style="text-indent:0em;">Consider administering oral vitamin K depending on INR, site of bleeding, risk of progression to more serious bleeding, and thrombotic risk.</p></td>
<td align="center">
<p style="text-indent:0em;">If administered, <b>oral</b> vitamin K 2.5 to 5 mg is recommended; if INR remains elevated after 24 hours, may administer another dose.<sup>b</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Major bleeding into a critical site and/or life- threatening bleeding (including intracranial hemorrhage)</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue warfarin and urgently administer a 4-factor PCC<sup>h</sup> in combination with IV vitamin K; monitor INR frequently and assess for hemostasis.</p></td>
<td align="center">
<p style="text-indent:0em;">Administer <b>IV </b>vitamin K 10 mg over 10 to 20 minutes (maximum infusion rate: 1 mg/minute) as soon as possible in combination with a 4-factor PCC; if INR remains elevated after 12 to 24 hours, may administer another dose of vitamin K.<sup>c,d,i,j</sup></p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>
<b>Invasive procedure or surgery</b></i></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Elective</p></td>
<td align="center">
<p style="text-indent:0em;">Thrombotic and bleeding risks vary depending on individual circumstances. Clinical practice guidelines may help guide whether to interrupt warfarin therapy, how long before an elective procedure or surgery warfarin should be discontinued (if necessary), whether bridging with a parenteral anticoagulant is needed, and when to restart warfarin therapy after the procedure/surgery.<sup>k,n</sup></p>
<p style="text-indent:0em;">If it is decided to discontinue warfarin, therapy is typically stopped 5 days before the procedure/surgery. If INR remains &gt;1.5 the day before the procedure/surgery, oral vitamin K may be considered but is not recommended routinely. Recheck INR on the day of the procedure/surgery.<sup>l,k</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Administer <b>oral</b> vitamin K 1 to 2.5 mg once if needed the day before the procedure/surgery.<sup>a,b,l</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Urgent</p></td>
<td align="center">
<p style="text-indent:0em;">For urgent procedures or surgeries in patients at high bleeding risk, vitamin K with or without a 4-factor PCC may be needed.</p></td>
<td align="center">
<p style="text-indent:0em;">Administer <b>IV</b> vitamin K 1 to 10 mg over 10 to 20 minutes (maximum infusion rate: 1 mg/minute) with or without a 4-factor PCC, depending on urgency of the procedure/surgery and risk of bleeding.<sup>l,m</sup></p>
<p style="text-indent:0em;">For patients with a mechanical prosthetic heart valve, some experts recommend low-dose <b>oral or IV</b> vitamin K (ie, 1 or 2 mg) in combination with a 4-factor PCC in order to balance risk of bleeding and valve thrombosis.<sup>o</sup></p>
<p style="text-indent:0em;">Refer to institutional policies and procedures.</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1e516107-a984-490b-b400-3b80f6d49964">Reversal of anticoagulation due to long-acting anticoagulant rodenticides</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of anticoagulation due to long-acting anticoagulant rodenticides: </b>Consultation with a clinical toxicologist or poison control center and hematologist is highly recommended when making treatment decisions, including dose, route, and duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Calello.1','lexi-content-ref-31797705','lexi-content-ref-30280655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Calello.1','lexi-content-ref-31797705','lexi-content-ref-30280655'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>No significant bleeding or minor bleeding (eg, epistaxis, ecchymosis):</i></b>
<b></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Ideal dosing has not been established.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>INR &lt;4.5 and no bleeding: </i>No vitamin K required; monitor and observe closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Calello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Calello.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>INR ≥4.5 or minor bleeding: </i>
<b>Oral:</b>
<i></i>Some experts recommend an initial dose of 10 mg per day in otherwise healthy patients; titrate as needed based on serial PT and INR measurements (eg, initially every 48 to 72 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Calello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Calello.1'])">Ref</a></span>). The reported daily dosage range is variable (up to 800 mg per day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14524650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14524650'])">Ref</a></span>)). Patients may require treatment for several months and should be under the care of a hematologist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Calello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Calello.1'])">Ref</a></span>); compliance with treatment and monitoring is of utmost importance during outpatient therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31797705','lexi-content-ref-31736367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31797705','lexi-content-ref-31736367'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Serious bleeding (eg, intracranial, GU, GI bleeding):</i></b>
<b></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Ideal dosing has not been established. For life-threatening bleeding, vitamin K should be administered in combination with clotting factors (eg, 4-factor prothrombin complex concentrate [PCC] or 3-factor PCC in combination with either recombinant factor VIIa or fresh frozen plasma if 4-factor PCC is not available) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31171018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31171018'])">Ref</a></span>). Treatment should begin with IV vitamin K and then transition to oral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Calello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Calello.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> Reported initial doses are variable and range from 10 to 300 mg per day; titrate as needed based on serial PT and INR measurements (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31797705','lexi-content-ref-21740137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31797705','lexi-content-ref-21740137'])">Ref</a></span>). Clinicians may choose to initiate therapy according to recommendations for reversal of anticoagulation due to warfarin or other coumarin or indandione derivatives at doses indicated for major bleeding at any INR elevation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Calello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Calello.1'])">Ref</a></span>). The reported daily dosage range is variable (up to 800 mg per day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14524650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14524650'])">Ref</a></span>)). Patients may require treatment with oral vitamin K for several months and should be under the care of a hematologist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Calello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Calello.1'])">Ref</a></span>); compliance with treatment and monitoring is of utmost importance during outpatient therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31797705','lexi-content-ref-31736367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31797705','lexi-content-ref-31736367'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf8fb0a2-1754-4225-8323-919356f08326">Vitamin K deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin K deficiency (without liver disease): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Vitamin K deficiency in healthy adults is rare; deficiency tends to be associated with specific conditions (eg, bariatric surgery, biliary disease, malnutrition, cystic fibrosis, prolonged use of broad-spectrum antibiotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pazirandeh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pazirandeh.1'])">Ref</a></span>). Avoid oral route in situations associated with GI malabsorption.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Treatment of coagulopathy: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral, SUBQ</b>: Usual dose: 10 mg once; may repeat in 48 to 72 hours if coagulopathy persists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pazirandeh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pazirandeh.1'])">Ref</a></span>); range: 1 to 25 mg (manufacturer's labeling); maximum IV infusion rate: 1 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315269'])">Ref</a></span>). <b>Note:</b> SUBQ administration is not recommended in patients with generalized edema (eg, anasarca) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pazirandeh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pazirandeh.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Bariatric surgery:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Prevention of vitamin K deficiency, supplementation:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Laparoscopic adjustable gastric band, Roux-en-Y gastric bypass, or sleeve gastrectomy:</i></b>
<b>Oral: </b>90 to 120 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31917200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31917200'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Biliopancreatic diversion/duodenal switch</i>:</b>
<b>Oral:</b> 300 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31917200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31917200'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Acute vitamin K repletion for malabsorption: </i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 10 mg once over 10 to 20 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31917200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31917200'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Chronic vitamin K repletion for malabsorption: </i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 1 to 2 mg once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31917200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31917200'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 1 to 2 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31917200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31917200'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In the United States and Canada, low-dose oral preparations can be found over the counter. A pharmacist can help the patient locate a low-dose supplement from a reliable supplier or prepare a compounded oral solution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cystic fibrosis with pancreatic insufficiency:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Prevention of vitamin K deficiency, supplementation</i>: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral: </b>2.5 to 5 mg once weekly. <b>Note: </b>Additional supplementation may be required during antibiotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14734689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14734689'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a068e7a-4ecd-47b8-9eb3-a7d59f8eada5">Liver disease, treatment of coagulopathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Liver disease, treatment of coagulopathy (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider use if vitamin K deficiency is suspected (eg, due to poor nutrition, cholestatic disease, diarrheal illness, or antibiotic use); vitamin K does not correct clotting factor deficiency due to parenchymal liver dysfunction and is not typically used for variceal bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Intagliata.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Intagliata.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Major bleeding (nonvariceal): </b>
<b>IV:</b> 10 mg once over 10 to 20 minutes (maximum infusion rate: 1 mg/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315269','lexi-content-ref-30986390','lexi-content-ref-Intagliata.1','lexi-content-ref-29194678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315269','lexi-content-ref-30986390','lexi-content-ref-Intagliata.1','lexi-content-ref-29194678'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Minor bleeding (nonvariceal):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 10 mg once daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Intagliata.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Intagliata.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 10 mg once over 10 to 20 minutes (maximum infusion rate: 1 mg/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315269','lexi-content-ref-30986390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315269','lexi-content-ref-30986390'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nonbleeding: Oral, IV, SUBQ:</b> 5 to 10 mg once (maximum IV infusion rate: 1 mg/minute). <b>Note:</b> Oral route is preferred unless there is concern for poor absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lee.2011','lexi-content-ref-30986390','lexi-content-ref-15710219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lee.2011','lexi-content-ref-30986390','lexi-content-ref-15710219'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27561ec2-c621-4e7d-867e-6b9d09d06acd">Warfarin-associated INR variation due to vitamin K deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Warfarin-associated INR variation due to vitamin K deficiency (off-label use</b>
<b>): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients with poor INR control due to suspected vitamin K deficiency (eg, insufficient dietary intake). Ensure proper warfarin adherence and consult with the anticoagulation specialist managing the patient before prescribing.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 100 to 200 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27232386','lexi-content-ref-21193422','lexi-content-ref-16305294','lexi-content-ref-17666020','lexi-content-ref-17110451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27232386','lexi-content-ref-21193422','lexi-content-ref-16305294','lexi-content-ref-17666020','lexi-content-ref-17110451'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In the United States and Canada, low-dose (eg, 100 mcg) oral preparations can be found over the counter. A pharmacist can help the patient locate a low-dose supplement from a reliable supplier or prepare a compounded oral solution.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991317"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (no unmetabolized vitamin K eliminated in urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (lipophilic characteristics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30646590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30646590'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (lipophilic characteristics): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988660"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F209734"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, flushing, hypotension, tachycardia, weak pulse</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, eczematous rash, erythema, erythematous rash, pruritic plaques of the skin, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (including pain, swelling, tenderness)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cyanosis, dyspnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Lesion (scleroderma-like)</p></div>
<div class="block coi drugH1Div" id="F209748"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to phytonadione or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F209731"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Cutaneous reactions have occurred after parenteral administration, including delayed-type hypersensitivity reactions, eczematous reactions, scleroderma-like patches, and urticaria; onset may occur within 1 day to a year. If skin reactions occur, discontinue therapy and treat appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/anaphylactoid reactions: Hypersensitivity reactions, including anaphylaxis, chest pain, cyanosis, diaphoresis, dyspnea, flushing, cardiorespiratory arrest, shock, tachycardia, weakness, and death, have occurred. Anaphylaxis typically, but not always, occurred when patients received large IV doses administered rapidly with formulations containing polyethoxylated castor oil (also called polyoxyethylated castor oil); proper dosing, dilution, and administration will minimize risk (ACCP [Ageno 2012]; Britt 2018; Riegert-Johnson 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant-induced coagulopathy: In patients receiving a therapeutic vitamin K antagonist (VKA) (eg, warfarin), administer a dose of phytonadione that will quickly lower the INR into a safe range without causing resistance to warfarin. High phytonadione doses (eg, &gt;10 to 15 mg) may lead to warfarin resistance for ≥1 week.</p>
<p style="text-indent:-2em;margin-left:4em;">• Liver disease, coagulopathy: If initial doses do not reverse coagulopathy, then higher doses are unlikely to have any effect. <b>Note:</b> Ineffective in hereditary hypoprothrombinemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Long-acting anticoagulant rodenticide (LAAR) ingestion: Patients with LAAR-induced coagulopathy require much larger doses and longer treatment durations (up to months) after exposure compared to that needed to reverse warfarin-induced coagulopathy (Devgun 2020; Gunja 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Use with caution in neonates, especially premature infants; severe hemolytic anemia, jaundice, and hyperbilirubinemia have been reported with larger than recommended doses (10 to 20 mg).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polyoxyethylated castor oil: Some injectable dosage forms contain polyoxyethylated castor oil (Cremophor EL) which is associated with hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate route: Oral administration is the safest and requires the presence of bile salts for absorption. In obstructive jaundice or with biliary fistulas, concurrent administration of bile salts would be necessary for proper absorption. Manufacturers recommend the SubQ route over other parenteral routes, however, SubQ is less predictable when compared to the oral route, and efficacy may be delayed. Therefore, the SubQ route has fallen out of favor due to erratic and unpredictable absorption (Crowther 2002; DeZee 2006; Raj 1999). The IV route may be used in selected <b>nonbleeding</b> patients and should be used in patients with <b>major bleeding</b> due to warfarin-associated coagulopathy (ACCP [Guyatt 2012]; Patriquin 2011). IM route should be avoided due to the risk of hematoma formation (except, for example, in the neonatal and pediatric populations for prevention/treatment of vitamin K deficiency bleeding). Efficacy (eg, control of bleeding, decrease in INR) is delayed regardless of route of administration; patient management may require other treatments in the interim.</p></div>
<div class="block dosfc drugH1Div" id="F25572881"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Injectable products may contain alcohol, benzyl alcohol, polysorbate 80, propylene glycol, or polyoxyethylated/polyethoxylated castor oil (Cremophor EL).</p></div>
<div class="block foc drugH1Div" id="F209741"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, aqueous colloidal: 1 mg/0.5 mL (0.5 mL); 10 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, aqueous colloidal [preservative free]: 1 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mephyton: 5 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: 100 mcg, 5 mg</p></div>
<div class="block geq drugH1Div" id="F209727"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F209750"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (K1-1000 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Phytonadione Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/0.5 mL (per 0.5 mL): $7.20 - $29.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $51.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Phytonadione Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $66.99</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block exp drugH1Div" id="F209746"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 1 mg/mL oral suspension may be made with tablets. Crush six 5 mg tablets in a mortar and reduce to a fine powder. Add 5 mL each of water and methylcellulose 1% and mix to a uniform paste. Mix while adding sorbitol in incremental proportions to <b>almost</b> 30 mL; transfer to a calibrated bottle, rinse mortar with sorbitol, and add quantity of sorbitol sufficient to make 30 mL. Label "shake well" and "refrigerate". Stable for 3 days.</p>
<div class="reference">Nahata MC, Hipple TF, <i>Pediatric Drug Formulations</i>. 3rd ed. Harvey Whitney Books Co; 1997.</div>
<p style="text-indent:0em;">
<b>Note:</b> The parenteral formulation may also be used for small oral doses (eg, 1 mg) or situations in which tablets cannot be swallowed (Crowther, 2000; O’Connor, 1986); may administer undiluted or diluted in a beverage (eg, orange juice) (Vanier 2006). Phytonadione IV solution administered orally has been shown to be as effective as orally administered tablets (Rice 2022).</p></div>
<div class="block admp drugH1Div" id="F52613588"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered with or without food. The parenteral formulation may also be used for small oral doses (eg, 1 mg) or situations in which tablets cannot be swallowed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11075768','lexi-content-ref-3514830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11075768','lexi-content-ref-3514830'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: <b>Note:</b> Limit IV administration to situations where an alternative route of administration is not feasible and the benefit of therapy outweighs the risk of hypersensitivity reactions; proper dosing, dilution, and administration will minimize risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315269','lexi-content-ref-12392385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315269','lexi-content-ref-12392385'])">Ref</a></span>). Allergic reactions have also occurred with IM and SUBQ injections, albeit less frequently.</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: Administer undiluted.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer undiluted; for use in neonatal patients, verify appropriate concentration (1 mg/0.5 mL).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: After dilution, infuse slowly. In pediatric patients, IV doses have been infused over 10 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007','lexi-content-ref-9822076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007','lexi-content-ref-9822076'])">Ref</a></span>); maximum rate of infusion: 1 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F209744"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> After dilution of dose in a minimum of 50 mL of compatible solution, administer slowly using an infusion pump over 10 to 20 minutes depending on dose at a rate not to exceed 1 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315269','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315269','lexi-content-ref-manu.1'])">Ref</a></span>). The injectable route should be used only if the oral route is not feasible or there is a greater urgency to reverse anticoagulation. The IV route may be used in selected nonbleeding patients and should be used in patients with major bleeding due to warfarin-associated coagulopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315257','lexi-content-ref-22077529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315257','lexi-content-ref-22077529'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> SUBQ route is generally not recommended due to erratic and unpredictable absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12186515','lexi-content-ref-16505257','lexi-content-ref-10597763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12186515','lexi-content-ref-16505257','lexi-content-ref-10597763'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> IM route should be avoided due to the risk of hematoma formation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> The parenteral formulation may also be used for small oral doses (eg, 1 mg) or situations in which tablets cannot be swallowed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11075768','lexi-content-ref-12186515','lexi-content-ref-3514830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11075768','lexi-content-ref-12186515','lexi-content-ref-3514830'])">Ref</a></span>); may administer undiluted or diluted in a beverage (eg, orange juice) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vanier.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vanier.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F209756"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Store intact ampules and vials in original container at 20°C to 25°C (68°F to 77°F); protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Store in original container at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes:</i> Guidelines suggest that at least 50 to 100 mg of phytonadione be stocked, including both oral and parenteral formulations. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53568363"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Prophylaxis and treatment of vitamin K deficiency bleeding in neonates (formerly known as hemorrhagic disease of the newborn) (FDA approved in neonates); treatment of anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives (FDA approved in adults); treatment of drug-induced hypoprothrombinemia (eg, salicylates, antibacterial agents) (FDA approved in adults); treatment of hypoprothrombinemia caused by malabsorption or inability to synthesize vitamin K (eg, obstructive jaundice, biliary fistula, ulcerative colitis, celiac disease, cystic fibrosis of the pancreas) (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; treatment of drug-induced hypoprothrombinemia (ie, salicylates or antibacterial agents); treatment of hypoprothrombinemia caused by obstructive jaundice or biliary fistulas (administered concurrently with bile acids) (All indications: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F209808"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Mephyton may be confused with melphalan, methadone</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299879"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F209735"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the absorption of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or 2 hours after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Phytonadione may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F50968389"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary adequate intake</b> (IOM 2001; Vanek 2012):</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 6 months: 2 <b>mcg</b>/day</p>
<p style="text-indent:-2em;margin-left:4em;">7 to 12 months: 2.5 <b>mcg</b>/day</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 3 years: 30 <b>mcg</b>/day</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 8 years: 55 <b>mcg</b>/day</p>
<p style="text-indent:-2em;margin-left:4em;">9 to 13 years: 60 <b>mcg</b>/day</p>
<p style="text-indent:-2em;margin-left:4em;">14 to 18 years: 75 <b>mcg</b>/day</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;18 years: Males: 120 <b>mcg</b>/day; Females: 90 <b>mcg</b>/day</p></div>
<div class="block pri drugH1Div" id="F10916304"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Phytonadione crosses the placenta in limited concentrations (Kazzi 1990).</p>
<p style="text-indent:0em;margin-top:2em;">The dietary requirements of vitamin K are the same in pregnant and nonpregnant women (IOM 2001). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Use of preservative free solutions are preferred when the injection is needed during pregnancy.</p></div>
<div class="block mopp drugH1Div" id="F53568351"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">PT, INR; monitor for hypersensitivity reactions if administering IV.</p></div>
<div class="block pha drugH1Div" id="F209730"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Promotes liver synthesis of clotting factors (II, VII, IX, X); however, the exact mechanism as to this stimulation is unknown. Menadiol is a water soluble form of vitamin K; phytonadione has a more rapid and prolonged effect than menadione; menadiol sodium diphosphate (K<sub>4</sub>) is half as potent as menadione (K<sub>3</sub>).</p></div>
<div class="block phk drugH1Div" id="F209747"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Increased coagulation factors: Oral: 6 to 10 hours; IV: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: INR values return to normal: Oral: 24 to 48 hours; IV: 12 to 14 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: From intestines in presence of bile; SUBQ: Variable; IM: Readily.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: As metabolites in urine and feces.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F209751"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Konakion mm</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Konakion mm | Vitamina k surar pharma | Vitamina k1 biol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Konakion</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Konakion</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Konakion</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Konakion</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Kanakion | Kanakion MM | Kavit | Vikatron | Vita K | Vitamina k</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Konakion</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fitoquinona | Konakion</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Kai nai jin | Vitamin K1</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fitomenadiona | Vitamina k | Vitamina K1</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Kanavit</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Kanavit | Vitamin K1</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Konakion</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fitomenadiona | Konakion</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Menadion medic</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adcokion | Epikavit | Haemokion | K Dion | K sabaa | Konakion | Origin k1 | Phytomenadion | Vitadione</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Konakion mm</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Konakion</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Vitamin K1</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Kaywan | Neo k</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Konakion mm</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Kenadion</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Konakion</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dekaywan | Ersupa k1 | Hymeron k1 | Kaywan | Keipole | Mephyton | Nichivita k1 | Onekey | Phytonadione merck | Phytonadione towa | Univitan k1 universal | Univitan k1 yoshindo | Vita k1 kobayashi | Vitamin k1 amel | Vitamin k1 daiko | Vitamin k1 fuso | Vitamin k1 meiji | Vitamin k1 mita | Vitamin k1 nipro | Vitamin k1 nisshin kyorin sei | Vitamin k1 pfizer | Vitamin k1 sawai | Vitamin k1 seiko | Vitamin k1 showa | Vitamin k1 taisho | Vitamin k1 tobishi</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Kaywan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Gnc Vitamin K | Konakion | Vitamin K</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Kanavit | Konakion | Konakion mm | Konakion novum</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Kanavit</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amidalak</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Vitamin K | Vitamin K1</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Konakion | Menadion | Vitacon | Vitacon campus</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Konakion mm | Vitamin K1</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Gnc Vitamin K</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Hema-k</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Vitamin K1</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Kanavit</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Mephyton | Phytonadione | Vitamin K</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fitomenadiona | Kanakion | Kanakion MM | Kanakion Mm Pediatrico</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Fitoquinona</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Kenadion | Konakion MM | Konakion MM Paediatric</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Amri k | Konakion</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Konakion</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Konakion mm</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Kanavit</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">K-vita | Konakion | Konakion mm</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Vitamine k1</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Konakion</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Kaywan | Konakion mm | Phynadin k | Phytonadione | Vitamin K1</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Kavit | Konakion | Konakion mm | Vitamina k</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hemo k | Vitamina k | Vitamina K1</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Konakion</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22315269">
<a name="22315269"></a>Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e44s-e88s. doi:10.1378/chest.11-2292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/22315269/pubmed" id="22315269" target="_blank">22315269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aluminum.1">
<a name="Aluminum.1"></a>Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics Committee on Nutrition. Kleinman RE, Greer FR, eds. <i>Pediatric Nutrition Handbook</i>. 8th ed. American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18574265">
<a name="18574265"></a>Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). <i>Chest</i>. 2008;133(6)(suppl):160s-198s. doi:10.1378/chest.08-0670<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/18574265/pubmed" id="18574265" target="_blank">18574265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31732375">
<a name="31732375"></a>Baugh CW, Levine M, Cornutt D, et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. <i>Ann Emerg Med</i>. 2020;76(4):470-485. doi:10.1016/j.annemergmed.2019.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/31732375/pubmed" id="31732375" target="_blank">31732375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12181071">
<a name="12181071"></a>Bolton-Maggs P, Brook L. The Use of Vitamin K for Reversal of Over-Warfarinization In Children. <i>Br J Haematol</i>. 2002;118(3):924.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/12181071/pubmed" id="12181071" target="_blank">12181071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12352509">
<a name="12352509"></a>Borowitz D, Baker RD, Stallings V. Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis. <i>J Pediatr Gastroenterol Nutr</i>. 2002;35(3):246-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/12352509/pubmed" id="12352509" target="_blank">12352509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28301903">
<a name="28301903"></a>Britt RB, Brown JN. Characterizing the severe reactions of parenteral vitamin K1. <i>Clin Appl Thromb Hemost. </i>2018;24(1):5-12. doi:10.1177/1076029616674825<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/28301903/pubmed" id="28301903" target="_blank">28301903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30100105">
<a name="30100105"></a>Bronsky J, Campoy C, Braegger C; ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Vitamins. <i>Clin Nutr</i>. 2018;37(6, pt B):2366-2378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/30100105/pubmed" id="30100105" target="_blank">30100105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Calello.1">
<a name="Calello.1"></a>Calello DP. Anticoagulant rodenticide poisoning: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25312896">
<a name="25312896"></a>Card DJ, Francis S, Deuchande K, Harrington DJ. Superwarfarin poisoning and its management. <i>BMJ Case Rep</i>. 2014;2014:bcr2014206360. doi:10.1136/bcr-2014-206360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/25312896/pubmed" id="25312896" target="_blank">25312896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30646590">
<a name="30646590"></a>Cozzolino M, Mangano M, Galassi A, Ciceri P, Messa P, Nigwekar S. Vitamin K in chronic kidney disease. <i>Nutrients</i>. 2019;11(1):168. doi:10.3390/nu11010168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/30646590/pubmed" id="30646590" target="_blank">30646590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Croteau.1">
<a name="Croteau.1"></a>Croteau SE. Bleeding. In Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th edition. Lippincott Williams &amp; Wilkins; 2022: chap. 43.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12186515">
<a name="12186515"></a>Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. <i>Ann Intern Med</i>. 2002;137(4):251-254. doi:10.7326/0003-4819-137-4-200208200-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/12186515/pubmed" id="12186515" target="_blank">12186515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11075768">
<a name="11075768"></a>Crowther MA, Julian J, McCarty D, et al. Treatment of Warfarin-associated Coagulopathy With Oral Vitamin K: A Randomised Controlled Trial. <i>Lancet</i>. 2000;356(9241):1551-1553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/11075768/pubmed" id="11075768" target="_blank">11075768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27232386">
<a name="27232386"></a>Dentali F, Crowther M, Galli M, et al; WARPED Investigators. Effect of vitamin K intake on the stability of treatment with vitamin K antagonists: a systematic review of the literature. <i>Semin Thromb Hemost</i>. 2016;42(6):671-681. doi:10.1055/s-0036-1581105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/27232386/pubmed" id="27232386" target="_blank">27232386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31797705">
<a name="31797705"></a>Devgun JM, Rasin A, Kim T, et al. An outbreak of severe coagulopathy from synthetic cannabinoids tainted with long-acting anticoagulant rodenticides. <i>Clin Toxicol.</i> 2020;58(8):821-828. doi:10.1080/15563650.2019.1690149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/31797705/pubmed" id="31797705" target="_blank">31797705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16505257">
<a name="16505257"></a>DeZee KJ, Shimeall WT, Douglas KM, Shumway NM, O'Malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. <i>Arch Intern Med</i>. 2006;166(4):391-397. doi:10.1001/.391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/16505257/pubmed" id="16505257" target="_blank">16505257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28081965">
<a name="28081965"></a>Doherty JU, Gluckman TJ, Hucker WJ, et al; 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation. <i>J Am Coll Cardiol</i>. 2017; 69(7):871-898. doi:10.1016/j.jacc.2016.11.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/28081965/pubmed" id="28081965" target="_blank">28081965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Douketis.1">
<a name="Douketis.1"></a>Douketis JD, Lip GYH. Perioperative management of patients receiving anticoagulants. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315266">
<a name="22315266"></a>Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e326s-e350s. doi:10.1378/chest.11-2298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/22315266/pubmed" id="22315266" target="_blank">22315266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35964704">
<a name="35964704"></a>Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. <i>Chest</i>. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/35964704/pubmed" id="35964704" target="_blank">35964704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dror.1">
<a name="Dror.1"></a>Dror Y, Chan AKC, Baker JM, and Avila ML. Hematology. In: MacDonald MG, Seshia MMK, eds. <i>Avery's Neonatology - Pathophysiology and Management of the Newborn</i>. 7th ed. Philadelphia, PA: Wolters Kluwer; 2016:chap 43.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC. <i>Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073738">
<a name="32073738"></a>Farrow GS, Delate T, McNeil K, et al. Vitamin K versus warfarin interruption alone in patients without bleeding and an international normalized ratio &gt;10. <i>J Thromb Haemost.</i> 2020;18(5):1133-1140. doi:10.1111/jth.14772<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/32073738/pubmed" id="32073738" target="_blank">32073738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31736367">
<a name="31736367"></a>Feinstein DL, Nosal DG, Ramanathan S, et al. Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. <i>Clin Toxicol (Phila)</i>. 2020;58(7):716-724. doi:10.1080/15563650.2019.1687903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/31736367/pubmed" id="31736367" target="_blank">31736367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21193422">
<a name="21193422"></a>Gebuis EP, Rosendaal FR, van Meegen E, van der Meer FJ. Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. <i>Haematologica</i>. 2011;96(4):583-589. doi:10.3324/haematol.2010.035162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/21193422/pubmed" id="21193422" target="_blank">21193422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21740137">
<a name="21740137"></a>Gunja N, Coggins A, Bidny S. Management of intentional superwarfarin poisoning with long-term vitamin K and brodifacoum levels. <i>Clin Toxicol (Phila)</i>. 2011;49(5):385-390. doi:10.3109/15563650.2011.587126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/21740137/pubmed" id="21740137" target="_blank">21740137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35190810">
<a name="35190810"></a>Hand I, Noble L, Abrams SA. Vitamin K and the newborn infant. <i>Pediatrics</i>. 2022;149(3):e2021056036. doi:10.1542/peds.2021-056036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/35190810/pubmed" id="35190810" target="_blank">35190810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18574259">
<a name="18574259"></a>Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ. Executive summary: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). <i>Chest</i>. 2008;133(6)(suppl):71s-109s. doi:10.1378/chest.08-0693<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/18574259/pubmed" id="18574259" target="_blank">18574259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315259">
<a name="22315259"></a>Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e152s-e184s. doi:10.1378/chest.11-2295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/22315259/pubmed" id="22315259" target="_blank">22315259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hull.1">
<a name="Hull.1"></a>Hull RD, Garcia DA. Management of warfarin-associated bleeding or supratherapeutic INR. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Intagliata.1">
<a name="Intagliata.1"></a>Intagliata N, Shah NL. Hemostatic abnormalities in patients with liver disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>Institute of Medicine (IOM). <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>. National Academy Press, 2001.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2304704">
<a name="2304704"></a>Kazzi NJ, Ilagan NB, Liang KC, Kazzi GM, Grietsell LA, Brans YW. Placental transfer of vitamin K1 in preterm pregnancy. <i>Obstet Gynecol</i>. 1990;75(3, pt 1):334-337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/2304704/pubmed" id="2304704" target="_blank">2304704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30280655">
<a name="30280655"></a>Kelkar AH, Smith NA, Martial A, Moole H, Tarantino MD, Roberts JC. An outbreak of synthetic cannabinoid-associated coagulopathy in Illinois. <i>N Engl J Med</i>. 2018;379(13):1216-1223. doi:10.1056/NEJMoa1807652<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/30280655/pubmed" id="30280655" target="_blank">30280655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31171018">
<a name="31171018"></a>Kuramatsu JB, Sembill JA, Huttner HB. Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage. <i>Crit Care</i>. 2019;23(1):206. doi:10.1186/s13054-019-2492-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/31171018/pubmed" id="31171018" target="_blank">31171018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lee.2011">
<a name="Lee.2011"></a>Lee WM, Larson AM, Stravitz RT. AASLD Position Paper: The management of acute liver failure: update 2011. Published September 2011. https://www.aasld.org/sites/default/files/2019-06/AcuteLiverFailureUpdate201journalformat1.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mephyton.1">
<a name="Mephyton.1"></a>Mephyton (phytonadione) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9822076">
<a name="9822076"></a>Michelson AD, Bovill E, Monagle P, et al. Antithrombic Therapy in Children. <i>Chest</i>. 1998;114(5)(suppl):748-769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/9822076/pubmed" id="9822076" target="_blank">9822076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27050049">
<a name="27050049"></a>Mihatsch WA, Braegger C, Bronsky J, et al. Prevention of vitamin K deficiency bleeding in newborn infants: a position paper by the ESPGHAN Committee on Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2016;63(1):123-129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/27050049/pubmed" id="27050049" target="_blank">27050049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31446606">
<a name="31446606"></a>Moia M, Squizzato A. Reversal agents for oral anticoagulant-associated major or life-threatening bleeding. <i>Intern Emerg Med</i>. 2019;14(8):1233-1239. doi:10.1007/s11739-019-02177-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/31446606/pubmed" id="31446606" target="_blank">31446606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315277">
<a name="22315277"></a>Monagle P, Chan A, Goldenberg NA, et al. Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). <i>Chest</i>. 2012;141(2)(suppl):e737-e801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/22315277/pubmed" id="22315277" target="_blank">22315277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30315016">
<a name="30315016"></a>Ng E, Loewy AD. Position Statement: Guidelines for vitamin K prophylaxis in newborns: A joint statement of the Canadian Paediatric Society and the College of Family Physicians of Canada. <i>Can Fam Physician</i>. 2018;64(10):736-739.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/30315016/pubmed" id="30315016" target="_blank">30315016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19931069">
<a name="19931069"></a>Nightingale S, Ng VL. Optimizing Nutritional Management in Children With Chronic Liver Disease. <i>Pediatr Clin North Am</i>. 2009;56(5):1161-1183.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/19931069/pubmed" id="19931069" target="_blank">19931069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-2492. doi:10.1161/CIR.0000000000000029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nkomo.1">
<a name="Nkomo.1"></a>Nkomo VT, Konkle BA. Anticoagulation for prosthetic heart valves: management of bleeding and invasive procedures. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33768191">
<a name="33768191"></a>Nosal DG, van Breemen RB, Haffner JW, Rubinstein I, Feinstein DL. Brodifacoum pharmacokinetics in acute human poisoning: implications for estimating duration of vitamin K therapy. <i>Toxicol Commun</i>. 2021;5(1):69-72. doi:10.1080/24734306.2021.1887637<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/33768191/pubmed" id="33768191" target="_blank">33768191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3514830">
<a name="3514830"></a>O'Connor ME, Addiego JE. Use of Oral Vitamin K1 to Prevent Hemorrhagic Disease of the Newborn Infant. <i>J Pediatr</i>. 1986;108(4):616-619.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/3514830/pubmed" id="3514830" target="_blank">3514830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30986390">
<a name="30986390"></a>O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA clinical practice update: coagulation in cirrhosis. <i>Gastroenterology</i>. 2019;157(1):34-43.e1. doi:10.1053/j.gastro.2019.03.070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/30986390/pubmed" id="30986390" target="_blank">30986390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332150">
<a name="33332150"></a>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/33332150/pubmed" id="33332150" target="_blank">33332150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22077529">
<a name="22077529"></a>Patriquin C, Crowther M. Treatment of warfarin-associated coagulopathy with vitamin K. <i>Expert Rev Hematol</i>. 2011;4(6):657-665. doi:10.1586/ehm.11.59<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/22077529/pubmed" id="22077529" target="_blank">22077529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pazirandeh.1">
<a name="Pazirandeh.1"></a>Pazirandeh S, Burns DL. Overview of vitamin K. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 28, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15710219">
<a name="15710219"></a>Pereira SP, Rowbotham D, Fitt S, Shearer MJ, Wendon J, Williams R. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. <i>J Hepatol</i>. 2005;42(3):365-370.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/15710219/pubmed" id="15710219" target="_blank">15710219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phytonadione.1">
<a name="Phytonadione.1"></a>Phytonadione injectable emulsion [prescribing information]. South El Monte, CA: International Medication Systems Ltd; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phytonadione.2">
<a name="Phytonadione.2"></a>Phytonadione injectable emulsion [prescribing information]. Warren, NJ: Cipla USA Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phytonadione.3">
<a name="Phytonadione.3"></a>Phytonadione injection [prescribing information]. Lake Forest, IL: Hospira Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10597763">
<a name="10597763"></a>Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. <i>Arch Intern Med</i>. 1999;159(22):2721-2724. doi:10.1001/archinte.159.22.2721<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/10597763/pubmed" id="10597763" target="_blank">10597763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16305294">
<a name="16305294"></a>Reese AM, Farnett LE, Lyons RM, Patel B, Morgan L, Bussey HI. Low-dose vitamin K to augment anticoagulation control. <i>Pharmacotherapy</i>. 2005;25(12):1746-1751. doi:10.1592/phco.2005.25.12.1746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/16305294/pubmed" id="16305294" target="_blank">16305294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34751053">
<a name="34751053"></a>Rice JH, Akpunonu P, Davis GA, et al. Intravenous phytonadione administered orally in reducing warfarin-related coagulopathy. <i>Clin Toxicol.</i> 2022;60(4):530-532. doi:10.1080/15563650.2021.1995871<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/34751053/pubmed" id="34751053" target="_blank">34751053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12392385">
<a name="12392385"></a>Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. <i>Ann Allergy Asthma Immunol</i>. 2002;89(4):400-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/12392385/pubmed" id="12392385" target="_blank">12392385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17666020">
<a name="17666020"></a>Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. <i>J Thromb Haemost</i>. 2007;5(10):2043-2048. doi:10.1111/j.1538-7836.2007.02715.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/17666020/pubmed" id="17666020" target="_blank">17666020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20702838">
<a name="20702838"></a>Sathe MN, Patel AS. Update in Pediatrics: Focus on Fat-Soluble Vitamins. <i>Nutr Clin Pract</i>. 2010;25(4):340-346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/20702838/pubmed" id="20702838" target="_blank">20702838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17110451">
<a name="17110451"></a>Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. <i>Blood</i>. 2007;109(6):2419-2423. doi:10.1182/blood-2006-09-049262<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/17110451/pubmed" id="17110451" target="_blank">17110451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22891232">
<a name="22891232"></a>Shneider BL, Magee JC, Bezerra JA, et al. Efficacy of Fat-Soluble Vitamin Supplementation in Infants With Biliary Atresia. <i>Pediatrics</i>. 2012;130(3):e607-e614.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/22891232/pubmed" id="22891232" target="_blank">22891232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29194678">
<a name="29194678"></a>Stravitz RT, Ellerbe C, Durkalski V, et al; Acute Liver Failure Study Group. Bleeding complications in acute liver failure. <i>Hepatology</i>. 2018;67(5):1931-1942. doi:10.1002/hep.29694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/29194678/pubmed" id="29194678" target="_blank">29194678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32680646">
<a name="32680646"></a>Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2020;76(5):594-622. doi:10.1016/j.jacc.2020.04.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/32680646/pubmed" id="32680646" target="_blank">32680646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14524650">
<a name="14524650"></a>Tsutaoka BT, Miller M, Fung SM, Patel MM, Olson KR. Superwarfarin and glass ingestion with prolonged coagulopathy requiring high-dose vitamin K1 therapy. <i>Pharmacotherapy</i>. 2003;23(9):1186-1189. doi:10.1592/phco.23.10.1186.32755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/14524650/pubmed" id="14524650" target="_blank">14524650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22730042">
<a name="22730042"></a>Vanek VW, Borum P, Buchman A, et al. A.S.P.E.N. Position Paper: Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi-trace Element Products. <i>Nutr Clin Pract</i>. 2012;27(4):440-491.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/22730042/pubmed" id="22730042" target="_blank">22730042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vanier.1">
<a name="Vanier.1"></a>Vanier MC, Ngo TT. Reversal of overanticoagulation with vitamin K1: A plea for oral administration. <i>Can J Hosp Pharm</i>. 2006;59:125-135.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VitaminK.1">
<a name="VitaminK.1"></a>Vitamin K<sub>1</sub> (phytonadione) injectable emulsion [prescribing information]. Lake Forest, IL: Hospira; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482765">
<a name="30482765"></a>Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. <i>Blood Adv</i>. 2018;2(22):3257-3291. doi:10.1182/bloodadvances.2018024893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/30482765/pubmed" id="30482765" target="_blank">30482765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14734689">
<a name="14734689"></a>Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. <i>Chest</i>. 2004;125(1)(suppl):1s-39s. doi:10.1378/chest.125.1_suppl.1s<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-k-phytonadione-phytomenadione-pediatric-drug-information/abstract-text/14734689/pubmed" id="14734689" target="_blank">14734689</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12704 Version 190.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
